The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The target is human Matrix Gla protein (MGP), UniProt P08493, a secreted extracellular matrix (ECM) protein in the osteocalcin/MGP family whose function depends on vitamin K–dependent γ-carboxylation and N-terminal phosphorylation. Retrieved sources consistently describe MGP as an 84-aa (~11–12 kDa) secreted Gla-family ECM protein expressed in vascular and cartilaginous tissues, matching the provided UniProt context. (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, alshahrani2020developmentofin pages 36-43)
Matrix Gla protein (MGP) is a small, secreted ECM protein (reported as 84 amino acids; ~11–12 kDa) synthesized by vascular smooth muscle cells (VSMCs) and other cell types (e.g., fibroblasts, chondrocytes, endothelial cells) and present in tissues such as arterial wall, heart, kidney, lung, bone, and cartilage. (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, neofytou2024vitaminkfor pages 1-2)
MGP belongs to the vitamin K–dependent Gla-proteins, whose defining feature is post-translational conversion of specific glutamate (Glu) residues to γ-carboxyglutamate (Gla) residues via a vitamin K–dependent reaction. In MGP, γ-carboxylation is repeatedly described as essential for calcium/mineral binding and anti-calcification function. (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, lau2025structuralandbiophysical pages 64-68)
A central concept in the field is that MGP exists as multiple circulating/tissue forms defined by two major post-translational modifications:
- γ-carboxylation of multiple Glu residues (vitamin K–dependent)
- phosphorylation of three N-terminal serines
A recent review summarizes four operational isoform classes:
- p-cMGP (phosphorylated + carboxylated): considered fully active
- dp-ucMGP (dephosphorylated + uncarboxylated): considered fully inactive
- dp-cMGP and p-ucMGP/ucMGP: intermediate forms. (galunska2024extrahepaticvitaminkdependent pages 3-5)
Figure evidence supporting this isoform framework and downstream mechanisms is shown in a 2024 review figure. (galunska2024extrahepaticvitaminkdependent media 9afb72d6)
Across recent reviews, the primary function of MGP is described as inhibition of ectopic calcification, particularly vascular calcification and cartilage/soft-tissue mineralization. Mechanistically, this is described as occurring through:
1) Direct mineral binding (hydroxyapatite adsorption) and inhibition of crystal nucleation/growth
2) Inhibition of osteogenic signaling in the vessel wall (notably via BMP-2/4 antagonism), limiting VSMC osteogenic transdifferentiation and apoptosis-linked calcification. (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, neofytou2024vitaminkfor pages 1-2)
A 2024 review provides specific residue-level mapping often used operationally in the MGP literature:
- Five γ-carboxylated glutamates reported at positions 2, 37, 41, 47, 52
- Three phosphorylated serines at positions 3, 6, 9
This PTM pattern is tied to the functional isoform concept (active p-cMGP vs inactive dp-ucMGP). (galunska2024extrahepaticvitaminkdependent pages 3-5)
Structural/biophysical work summarized in a 2025 source likewise emphasizes an N-terminal intrinsically disordered region bearing phosphorylation (Ser3/6/9) and γ-carboxylation (including Gla2) alongside Gla residues near/within the folded core; Ca2+ binding and Gla chemistry stabilize structure and promote mineral binding. (lau2025structuralandbiophysical pages 52-55, lau2025structuralandbiophysical pages 18-21)
Active MGP is described as binding Ca2+ via Gla residues and binding to hydroxyapatite, thereby inhibiting hydroxyapatite crystal growth in extracellular contexts. (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 52-55, lau2025structuralandbiophysical pages 18-21)
A recent mechanistic summary figure illustrates that active MGP reduces hydroxyapatite crystal growth and can form mineral complexes that are cleared (phagocytosis/apoptosis framework). (galunska2024extrahepaticvitaminkdependent media 9afb72d6)
MGP is repeatedly described as binding BMP-2 (and BMP-4) and blocking osteogenic signaling in vascular tissues. In a 2024 review, this is framed as preventing VSMC osteogenic transition and inhibiting apoptosis-associated calcification. (galunska2024extrahepaticvitaminkdependent pages 3-5)
Structural/biophysical evidence summarized in 2025 emphasizes Ca2+/Gla dependence for BMP binding (BMP-2/4) and highlights that Gla/Ca2+ chemistry is required for this antagonism. (lau2025structuralandbiophysical pages 18-21, lau2025structuralandbiophysical pages 61-64)
Beyond minerals and BMPs, MGP has been described as interacting with ECM proteins; a 2025 source reports a C-terminal region that mediates binding to ECM proteins such as vitronectin and fibronectin, supporting an ECM-anchored role at calcification-prone sites. (lau2025structuralandbiophysical pages 18-21, lau2025structuralandbiophysical pages 61-64)
The functional setting for MGP is extracellular, within the vascular wall ECM and other soft-tissue/cartilage matrices. Expression is described in VSMCs, chondrocytes, fibroblasts, and endothelial cells, with tissue localization including arteries/arterial wall and multiple organs (heart, kidney, lung). (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, neofytou2024vitaminkfor pages 1-2)
Recent reviews emphasize that MGP is not merely associated with calcification but is causal in suppressing it:
- Genetic knockout in animal models causes rapid arterial calcification and fatal aortic rupture, supporting a critical anti-calcification role. (neofytou2024vitaminkfor pages 1-2)
- Reviews and mechanistic discussions connect inhibition of vitamin K–dependent carboxylation (e.g., warfarin) to loss of MGP activation and accelerated vascular/valvular calcification in model systems. (lau2025structuralandbiophysical pages 18-21, lau2025structuralandbiophysical pages 64-68)
Human loss-of-function in MGP is referenced in the context of Keutel syndrome, supporting the importance of intact MGP function for preventing aberrant mineralization. (yeasmin2022atransgenicapproach pages 6-10, tintut2021biomoleculesorchestratingcardiovascular pages 9-10)
A 2024 narrative review focuses on extrahepatic vitamin K–dependent proteins and highlights that MGP PTM states generate multiple isoforms with distinct functional interpretations (active p-cMGP vs inactive dp-ucMGP). It also stresses that relationships between specific MGP forms, vascular calcification, and cardiovascular pathology remain incompletely resolved—an active research and validation area. (galunska2024extrahepaticvitaminkdependent pages 3-5)
A 2024 Nutrients review positions MGP as a central vitamin K–dependent vascular calcification inhibitor in CKD, emphasizing that CKD patients often have vitamin K deficiency (dietary restriction, medications, absorption issues) and that circulating inactive MGP is used as a biomarker of vitamin K status; it also notes inconsistency of supplementation trials for clinical calcification outcomes. (neofytou2024vitaminkfor pages 1-2)
A 2023 review on vitamin K–dependent proteins in biomineralization highlights MGP among VK-dependent regulators and situates vitamin K antagonism as a risk factor for vascular/valvular calcification; it also notes MK-7 supplementation as a potential modifier of vascular calcification progression in coronary artery disease, reflecting continued interest in vitamin K → MGP activation as a modifiable axis. (zhang2023rolesofvitamin pages 4-6)
dp-ucMGP (dephospho-uncarboxylated MGP) is widely used as an inverse biomarker of extrahepatic functional vitamin K status, reflecting an “inactive MGP” pool. (lauridsen2025investigatingtheassociations pages 1-2, galunska2024extrahepaticvitaminkdependent pages 5-7)
Reviews emphasize biomarker promise (associations with arterial stiffness, calcification scores, CVD risk) but also highlight that validation and standardization across cohorts and outcomes remain ongoing. (galunska2024extrahepaticvitaminkdependent pages 14-16)
A 2023 systematic review and meta-analysis of randomized trials in dialysis patients (11 trials; 830 participants) found vitamin K supplementation improves vitamin K status and lowers dp-ucMGP, with stronger pooled reductions for vitamin K1 than vitamin K2 (standardized mean difference (SMD) −1.64 vs −0.56, respectively). However, despite biomarker changes, the meta-analysis reports no mortality effect and no significant improvement in calcification scores, underscoring the current translational gap between MGP activation biomarkers and hard clinical endpoints. (andrian2023vitaminksupplementation pages 1-3)
A 2024 review proposes a practical implication: avoiding vitamin K antagonists when possible (and considering DOACs) to preserve vitamin K–dependent activation of extrahepatic Gla-proteins such as MGP, while noting that DOAC/statin effects on these pathways require further study. (galunska2024extrahepaticvitaminkdependent pages 14-16)
A large cross-sectional adult population study measured plasma dp-ucMGP in 4,092 adults (ages 24–77) and analyzed associations per doubling of dp-ucMGP. Reported adjusted associations include:
- Central obesity: OR 4.76 (95% CI 3.57–6.34)
- Diabetes: OR 1.96 (95% CI 1.11–3.45)
- Hyperlipidaemia: OR 1.43 (95% CI 1.01–2.03)
- Impaired kidney function: OR 9.83 (95% CI 5.49–17.59)
No independent association was found with hypertension or arterial stiffness. This provides recent quantitative support that “inactive MGP/vitamin K status” is linked to cardiometabolic risk factors at population scale, while not necessarily tracking all vascular function endpoints. (lauridsen2025investigatingtheassociations pages 1-2)
In dialysis RCTs summarized by meta-analysis (11 trials; 830 total participants), vitamin K supplementation lowered dp-ucMGP (SMD −1.64 for K1; −0.56 for K2) but did not improve calcification scores or mortality in pooled analyses, providing a quantitative benchmark for real-world implementation limitations. (andrian2023vitaminksupplementation pages 1-3)
Recent reviews converge on a dual-mechanism model:
1) Mineral phase control: carboxylated/phosphorylated MGP binds Ca2+ and hydroxyapatite to inhibit crystal growth and participate in mineral complex handling.
2) Signaling control: MGP antagonizes BMP-2/4 to prevent osteogenic transdifferentiation in the vessel wall.
This framework is explicitly described and visually summarized in recent review material. (galunska2024extrahepaticvitaminkdependent pages 3-5, galunska2024extrahepaticvitaminkdependent media 9afb72d6)
Multiple recent sources emphasize that, while dp-ucMGP is widely used as a vitamin K status/inactive MGP marker, the mapping from MGP isoform levels to calcification burden and clinical events is not fully settled and may be context-dependent (population, CKD stage, assay/form measured, endpoint). (galunska2024extrahepaticvitaminkdependent pages 3-5, galunska2024extrahepaticvitaminkdependent pages 14-16, andrian2023vitaminksupplementation pages 1-3)
Gene/Protein: MGP (human; UniProt P08493)
Primary function: Secreted extracellular matrix protein that prevents ectopic mineralization, especially in the vascular wall and cartilage, by (i) Ca2+/Gla-dependent binding to hydroxyapatite and inhibition of mineral nucleation/growth and (ii) antagonism of osteogenic BMP signaling (BMP-2/4), limiting osteogenic conversion of vascular smooth muscle cells. (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, neofytou2024vitaminkfor pages 1-2)
Key enabling biochemistry: Requires vitamin K–dependent γ-carboxylation of five Glu residues and phosphorylation of three N-terminal Ser residues; the fully inactive circulating form dp-ucMGP is used as an inverse biomarker of functional vitamin K status. (galunska2024extrahepaticvitaminkdependent pages 3-5, galunska2024extrahepaticvitaminkdependent media 9afb72d6)
Cellular location: Secreted into extracellular matrix of the arterial wall and other tissues; produced notably by VSMCs and also by fibroblasts, chondrocytes, and endothelial cells. (galunska2024extrahepaticvitaminkdependent pages 3-5, neofytou2024vitaminkfor pages 1-2)
| Topic | Current understanding | Key evidence (with citation IDs) | Key recent sources (year; DOI/URL if in evidence) |
|---|---|---|---|
| Protein size / processing | Human MGP (UniProt P08493) is an 84-aa, ~11–12 kDa secreted extracellular matrix Gla-family protein made as a precursor with a signal peptide; literature consistently places it in the osteocalcin/MGP family and describes extracellular function in vessel wall/cartilage matrices. | 84-aa secreted ECM protein; extracellular localization; family-consistent Gla protein features (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, alshahrani2020developmentofin pages 36-43) | Galunska et al., 2024, Int J Mol Sci; https://doi.org/10.3390/ijms25063517. Lau, 2025 thesis/source (no DOI in evidence). |
| PTMs: γ-carboxylation | MGP activity depends on vitamin K–dependent γ-carboxylation of 5 Glu residues, commonly reported at positions 2, 37, 41, 47/48, and 52. Carboxylation is essential for Ca²⁺/mineral binding and anti-calcification activity; warfarin or loss of carboxylation causes inactive MGP and severe ectopic calcification in models. | Specific Gla positions and carboxylation dependence; loss-of-function/warfarin evidence (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, lau2025structuralandbiophysical pages 64-68, wen2018vitaminkdependentproteins pages 2-4) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. |
| PTMs: phosphorylation | Three N-terminal serines (Ser3, Ser6, Ser9) are phosphorylated. Phosphorylation helps define circulating/functional isoforms and likely modulates local conformation, secretion/mineral interaction, and full activity; p-cMGP is considered the fully active form, whereas dp-ucMGP is fully inactive. | Ser3/6/9 phosphorylation and isoform logic (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 52-55, wen2018vitaminkdependentproteins pages 2-4, galunska2024extrahepaticvitaminkdependent media 9afb72d6) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Figure summarizing isoforms and effects (galunska2024extrahepaticvitaminkdependent media 9afb72d6). |
| Major mechanism: hydroxyapatite binding / inhibition | Carboxylated MGP binds Ca²⁺ and adsorbs to hydroxyapatite, directly inhibiting nucleation/growth of mineral crystals in the extracellular matrix. This is a core anti-calcification mechanism in vessels and soft tissues. | Hydroxyapatite binding and inhibition of crystal growth (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 52-55, lau2025structuralandbiophysical pages 64-68, lau2025structuralandbiophysical pages 18-21) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. |
| Major mechanism: fetuin-A / mineral complexes | Active MGP can participate in mineralization complexes with fetuin-A, calcium, and phosphate, limiting crystal growth and promoting clearance of mineral-containing complexes/apoptotic material. | Fetuin-A/Ca–PO4 complex formation and phagocytic clearance model (galunska2024extrahepaticvitaminkdependent pages 3-5, wen2018vitaminkdependentproteins pages 2-4, galunska2024extrahepaticvitaminkdependent media 9afb72d6) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. |
| Major mechanism: BMP-2/4 antagonism | MGP binds BMP-2 and BMP-4 in a Ca²⁺/Gla-dependent manner and blocks BMP-driven osteogenic/chondrogenic conversion of vascular smooth muscle cells, thereby suppressing a key signaling route to vascular calcification. | BMP-2/4 antagonism and dependence on Gla/Ca²⁺ (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, lau2025structuralandbiophysical pages 61-64) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Lau, 2025 thesis/source (no DOI in evidence). |
| Localization / expressing cell types | MGP is secreted into extracellular matrix, especially in arterial wall/cartilage environments. It is produced by vascular smooth muscle cells, chondrocytes, fibroblasts, endothelial cells, and also reported in osteoblast/osteoclast-related contexts; tissue expression includes arteries, heart, kidney, lung, bone, and cartilage. | Cell types and tissue distribution (galunska2024extrahepaticvitaminkdependent pages 3-5, lau2025structuralandbiophysical pages 18-21, yeasmin2022atransgenicapproach pages 6-10, neofytou2024vitaminkfor pages 1-2) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. |
| Disease relevance / genetics | MGP is one of the strongest endogenous inhibitors of vascular and soft-tissue calcification. Human deficiency causes Keutel syndrome, while Mgp knockout animals develop rapid arterial/cartilage calcification and aortic rupture, supporting a causal anti-mineralization role rather than a passive association. | Human/animal loss-of-function phenotypes (yeasmin2022atransgenicapproach pages 6-10, lau2025structuralandbiophysical pages 18-21, neofytou2024vitaminkfor pages 1-2, tintut2021biomoleculesorchestratingcardiovascular pages 9-10) | Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. Zhang et al., 2023; https://doi.org/10.3892/ijmm.2023.5330. |
| Translational note: dp-ucMGP biomarker | Circulating dp-ucMGP (dephospho-uncarboxylated MGP) is the fully inactive form and an inverse biomarker of extrahepatic vitamin K status. It is widely studied in CKD/CVD risk stratification, but its specificity as a calcification marker remains imperfect and context-dependent. | Biomarker interpretation and cautions (galunska2024extrahepaticvitaminkdependent pages 3-5, galunska2024extrahepaticvitaminkdependent pages 14-16, galunska2024extrahepaticvitaminkdependent pages 5-7) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Nyvad et al., 2024; https://doi.org/10.1186/s12882-024-03876-5. |
| Recent quantitative biomarker / intervention data | In 4,092 adults, each doubling of dp-ucMGP associated with central obesity OR 4.76, diabetes OR 1.96, hyperlipidaemia OR 1.43, and impaired kidney function OR 9.83; no independent association with hypertension or arterial stiffness. In a 2023 meta-analysis of 11 randomized dialysis trials (830 participants), vitamin K lowered dp-ucMGP, with larger pooled effects for K1 (SMD −1.64) than K2 (SMD −0.56), but without clear mortality or calcification-score benefit. | Population-level ORs; trial/meta-analysis effect sizes (lauridsen2025investigatingtheassociations pages 1-2, andrian2023vitaminksupplementation pages 1-3) | Lauridsen et al., 2025 online/2024 DOI record; https://doi.org/10.1007/s00394-024-03532-6. Andrian et al., 2023; https://doi.org/10.1093/ckj/sfad255. |
Table: This table summarizes verified functional annotation facts for human Matrix Gla protein (MGP; UniProt P08493), including core biochemistry, mechanisms, localization, and translational biomarker relevance. It is designed as a compact evidence map for use in a gene-focused research report.
A 2024 review figure summarizes MGP post-translational activation (γ-carboxylation and phosphorylation), the major isoforms (dp-ucMGP, dp-cMGP, p-cMGP), and proposed anti-calcification actions (hydroxyapatite crystal growth inhibition and BMP-2 antagonism). (galunska2024extrahepaticvitaminkdependent media 9afb72d6)
References
(galunska2024extrahepaticvitaminkdependent pages 3-5): Bistra Galunska, Yoto Yotov, Miglena Nikolova, and Atanas Angelov. Extrahepatic vitamin k-dependent gla-proteins–potential cardiometabolic biomarkers. International Journal of Molecular Sciences, 25:3517, Mar 2024. URL: https://doi.org/10.3390/ijms25063517, doi:10.3390/ijms25063517. This article has 19 citations.
(lau2025structuralandbiophysical pages 18-21): YS Lau. Structural and biophysical characterization of human matrix gla protein. Unknown journal, 2025.
(alshahrani2020developmentofin pages 36-43): S Alshahrani. Development of in vitro and in vivo models to study the effects of a mutation in the signal peptide and posttranslational gamma carboxylation of mgp. Unknown journal, 2020.
(neofytou2024vitaminkfor pages 1-2): Ioannis Eleftherios Neofytou, Aikaterini Stamou, Antonia Demopoulos, Stefanos Roumeliotis, Pantelis Zebekakis, Vassilios Liakopoulos, Eleni Stamellou, and Evangelia Dounousi. Vitamin k for vascular calcification in kidney patients: still alive and kicking, but still a lot to learn. Nutrients, 16:1798, Jun 2024. URL: https://doi.org/10.3390/nu16121798, doi:10.3390/nu16121798. This article has 17 citations.
(lau2025structuralandbiophysical pages 64-68): YS Lau. Structural and biophysical characterization of human matrix gla protein. Unknown journal, 2025.
(galunska2024extrahepaticvitaminkdependent media 9afb72d6): Bistra Galunska, Yoto Yotov, Miglena Nikolova, and Atanas Angelov. Extrahepatic vitamin k-dependent gla-proteins–potential cardiometabolic biomarkers. International Journal of Molecular Sciences, 25:3517, Mar 2024. URL: https://doi.org/10.3390/ijms25063517, doi:10.3390/ijms25063517. This article has 19 citations.
(lau2025structuralandbiophysical pages 52-55): YS Lau. Structural and biophysical characterization of human matrix gla protein. Unknown journal, 2025.
(lau2025structuralandbiophysical pages 61-64): YS Lau. Structural and biophysical characterization of human matrix gla protein. Unknown journal, 2025.
(yeasmin2022atransgenicapproach pages 6-10): L Yeasmin. A transgenic approach to understand the role of the n'-terminal sequence of matrix gla protein in the prevention of ectopic calcification. Unknown journal, 2022.
(tintut2021biomoleculesorchestratingcardiovascular pages 9-10): Yin Tintut, Henry M. Honda, and Linda L. Demer. Biomolecules orchestrating cardiovascular calcification. Biomolecules, 11:1482, Oct 2021. URL: https://doi.org/10.3390/biom11101482, doi:10.3390/biom11101482. This article has 24 citations.
(zhang2023rolesofvitamin pages 4-6): Meng Zhang, Qingqi Zhang, Pengfei Du, Xin Chen, and Yumei Zhang. Roles of vitamin k-dependent protein in biomineralization (review). International Journal of Molecular Medicine, Nov 2023. URL: https://doi.org/10.3892/ijmm.2023.5330, doi:10.3892/ijmm.2023.5330. This article has 24 citations and is from a peer-reviewed journal.
(lauridsen2025investigatingtheassociations pages 1-2): Julie Aaberg Lauridsen, Katja Biering Leth-Møller, Line Tang Møllehave, Line Lund Kårhus, Thomas Meinertz Dantoft, Klaus Fuglsang Kofoed, and Allan Linneberg. Investigating the associations between uncarboxylated matrix gla protein as a proxy for vitamin k status and cardiovascular disease risk factors in a general adult population. European Journal of Nutrition, Nov 2025. URL: https://doi.org/10.1007/s00394-024-03532-6, doi:10.1007/s00394-024-03532-6. This article has 6 citations and is from a domain leading peer-reviewed journal.
(galunska2024extrahepaticvitaminkdependent pages 5-7): Bistra Galunska, Yoto Yotov, Miglena Nikolova, and Atanas Angelov. Extrahepatic vitamin k-dependent gla-proteins–potential cardiometabolic biomarkers. International Journal of Molecular Sciences, 25:3517, Mar 2024. URL: https://doi.org/10.3390/ijms25063517, doi:10.3390/ijms25063517. This article has 19 citations.
(galunska2024extrahepaticvitaminkdependent pages 14-16): Bistra Galunska, Yoto Yotov, Miglena Nikolova, and Atanas Angelov. Extrahepatic vitamin k-dependent gla-proteins–potential cardiometabolic biomarkers. International Journal of Molecular Sciences, 25:3517, Mar 2024. URL: https://doi.org/10.3390/ijms25063517, doi:10.3390/ijms25063517. This article has 19 citations.
(andrian2023vitaminksupplementation pages 1-3): Titus Andrian, Anca Stefan, Ionut Nistor, and Adrian Covic. Vitamin k supplementation impact in dialysis patients: a systematic review and meta-analysis of randomized trials. Clinical Kidney Journal, 16:2738-2749, Oct 2023. URL: https://doi.org/10.1093/ckj/sfad255, doi:10.1093/ckj/sfad255. This article has 5 citations and is from a peer-reviewed journal.
(wen2018vitaminkdependentproteins pages 2-4): Lianpu Wen, Jiepeng Chen, Lili Duan, and Shuzhuang Li. Vitamin k-dependent proteins involved in bone and cardiovascular health. Molecular Medicine Reports, 18:3-15, Apr 2018. URL: https://doi.org/10.3892/mmr.2018.8940, doi:10.3892/mmr.2018.8940. This article has 208 citations and is from a peer-reviewed journal.